GSK Broadens Scope Of Clinical Studies For Breast Cancer Therapy Lapatinib
This article was originally published in The Pink Sheet Daily
Executive Summary
The company outlined an expanded Phase III development program for Tykerb (lapatinib) during an oncology R&D update.